MCL1 and hematopoietic and lymphoid cell neoplasm: The development of the Mcl-1 inhibitor S63845 has enabled the selective inhibition of Mcl-1 in cancer cells, and S63845 has shown high efficacy in a panel of hematological cancer cell lines [42,63].